ADC Therapeutics Halts ADCT-502 Development, Phase 1 Trial for HER2-positive Cancers

ADC Therapeutics Halts ADCT-502 Development, Phase 1 Trial for HER2-positive Cancers
ADC Therapeutics has halted the development of ADCT-502, an investigational treatment candidate for HER2-positive solid cancers, and terminated its Phase 1 trial after it failed to show sufficient patient benefit, the company recently announced. The decision was based on data from the Phase 1 trial (NCT03125200) that showed that ADCT-502 did not meet the necessary efficacy and safety profile required for patient benefit. ADC plans to publish the findings of the trial later this year after it has evaluated all the data. “ADC Therapeutic's strategy is to progress a deep pipeline of ADCs into Phase 1 in order to assess their clinical and market potential based on actual human data, and only to progress into later stage development those ADCs that demonstrate the potential to be best in class in areas of high unmet medical need,” Chris Martin, CEO of ADCT, said in a press release. ADCT-502 is antibody-drug conjugate composed of an anti-HER2 antibody bound to a toxic compound. After binding to an HER2-positive cell, it releases its payload, leading to the cell's death without harming healthy tissues. The antibody used in ADCT-502, called trastuzumab, is already approved for certain HER2-positive cancers, including metastatic breast cancer. This antibody is marketed by Roche under the brand name Herceptin. But
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.